[HTML][HTML] A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
SK Padda, KL Reckamp, M Koczywas, JW Neal… - Cancer chemotherapy …, 2022 - Springer
Introduction Preclinical evidence suggests the feedforward cytokine loop of interleukin-
6/Janus kinases (JAK)/STAT3 plays a role in epidermal growth factor receptor tyrosine …
6/Janus kinases (JAK)/STAT3 plays a role in epidermal growth factor receptor tyrosine …
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
SK Padda, KL Reckamp… - Cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction Preclinical evidence suggests the feedforward cytokine loop of interleukin-
6/Janus kinases (JAK)/STAT3 plays a role in epidermal growth factor receptor tyrosine …
6/Janus kinases (JAK)/STAT3 plays a role in epidermal growth factor receptor tyrosine …
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
SK Padda, KL Reckamp, M Koczywas… - Cancer …, 2022 - search.ebscohost.com
Introduction: Preclinical evidence suggests the feedforward cytokine loop of interleukin-
6/Janus kinases (JAK)/STAT3 plays a role in epidermal growth factor receptor tyrosine …
6/Janus kinases (JAK)/STAT3 plays a role in epidermal growth factor receptor tyrosine …
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
SK Padda, KL Reckamp, M Koczywas… - Cancer …, 2021 - europepmc.org
Methods In this phase 1b study, the JAK1/2 and TANK-binding kinase 1 (TBK1) inhibitor
momelotinib was evaluated in combination with erlotinib in patients with EGFR TKI-naive …
momelotinib was evaluated in combination with erlotinib in patients with EGFR TKI-naive …
[HTML][HTML] A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
SK Padda, KL Reckamp, M Koczywas… - Cancer …, 2022 - ncbi.nlm.nih.gov
Methods In this phase 1b study, the JAK1/2 and TANK-binding kinase 1 (TBK1) inhibitor
momelotinib was evaluated in combination with erlotinib in patients with EGFR TKI-naive …
momelotinib was evaluated in combination with erlotinib in patients with EGFR TKI-naive …
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
SK Padda, KL Reckamp, K Marianna… - Cancer …, 2022 - search.proquest.com
Methods In this phase 1b study, the JAK1/2 and TANK-binding kinase 1 (TBK1) inhibitor
momelotinib was evaluated in combination with erlotinib in patients with EGFR TKI-naive …
momelotinib was evaluated in combination with erlotinib in patients with EGFR TKI-naive …